BioSpace News Archive

MiNK Therapeutics (Nasdaq: INKT) today presented preclinical data demonstrating the potential of its novel FAP-CAR-iNKT candidate, MiNK-215, at the American Society of Gene and Cell Therapy (ASGCT) annual meeting.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Hepatology Communications published data from the CAMEO study evaluating the safety, tolerability, and efficacy of LIVMARLI® (maralixibat) oral solution in patients with primary sclerosing cholangitis (PSC).

Bausch Health Companies Inc. today announced the publication of a new study, which showed that ARESTIN (minocycline HCI) microspheres, 1mg decreased certain pathogenic burdens, also known as infection burdens, in adults with periodontitis when applied immediately after scaling and root planning (SRP) and again at a three-month reapplication, versus SRP alone.

CARsgen Therapeutics Holdings Limited announced that CARsgen has initiated patient enrollment for Phase 2 of the clinical trial for CT041 in the U.S., for the treatment of CLDN18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies.

After record-setting investment peaks in FY 2020 and 2021 for synthetic biology, the field raised $10.3 billion in 2022.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced new nonclinical data supporting the use of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California.

Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.

Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that the US Food and Drug Administration (FDA) 510(k) has cleared “Neurophet AQUA”.

Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease by providing the most robust and clinically-proven total disc replacement technology platform in the world, announced record first quarter 2023 worldwide financial results in its Motion Preservation business.

Kiyatec, Inc., the leader in functional precision oncology, announced a new investment from the venture philanthropy arms of two leading brain tumor patient organizations.